Collection probe and method for use thereof

The described method and apparatus allow for non-destructive, real-time molecular evaluation of tissues using mass spectrometry, overcoming the limitations of current techniques by providing accurate differentiation between diseased and normal tissues.

JP2024156668AActive Publication Date: 2024-11-06BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024107850
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-02-23
Filing Date
2024-07-04
Publication Date
2024-11-06
Estimated Expiration
2037-08-31

AI Technical Summary

Technical Problem

Current methods for evaluating tissue samples, particularly in cancer diagnosis, suffer from freezing artifacts that distort tissue architecture and cell morphology, making it difficult to identify specific tumor cells, and lack effective molecular evaluation techniques.

Method used

A method and apparatus using a probe to apply a solvent to a tissue site, collect a liquid sample, and subject it to mass spectrometry analysis, with a system comprising a chamber, pressurized gas supply, and mass spectrometer, allowing for non-destructive, real-time molecular evaluation of tissues.

Benefits of technology

Enables accurate, real-time differentiation between diseased and normal tissues by obtaining mass spectrometry profiles without causing tissue damage, facilitating precise surgical interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156668000001_ABST
    Figure 2024156668000001_ABST
Patent Text Reader

Abstract

To provide a method and a device for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis.SOLUTION: In certain aspects, devices for the embodiments allow for the collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis. The device comprises: a chamber including a solvent; a compression gas supply part; a mass spectro-meter; and a probe including a reservoir, a first conduit, a second conduit, and a third conduit. The reservoir is in fluid connection with the first, second, and third conduits. The first solvent conduit is in fluid connection with the chamber, the second gas conduit is in fluid connection with the compression gas supply part, and the third collection conduit is in fluid connection with the mass spectro meter.SELECTED DRAWING: Figure 1E
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of U.S. Provisional Patent Application Nos. 62 / 383,234, filed September 2, 2016; 62 / 411,321, filed October 21, 2016; and 62 / 462,524, filed February 23, 2017, each of which is incorporated by reference in its entirety.

[0002] This invention was made with Government support under Grant No. R00 CA190783 awarded by the National Institutes of Health. The Government has certain rights in this invention.

[0003] 1. Field of the invention The present invention relates generally to the fields of medicine, molecular biology and biochemistry. In particular, the present invention relates to methods and devices for the evaluation of tissue samples using mass spectrometry. [Background technology]

[0004] 2. Description of Related Technology Clinical diagnosis is commonly performed by evaluation of tissue samples before, during, and after surgery, and at several other stages of the patient's treatment process. Tissue evaluation is crucial in the diagnosis and management of cancer patients. Intraoperative pathological evaluation of excised tissue is routinely performed, for example, for diagnosis and resection fragment evaluation in various cancer surgeries. The resected tissue samples are sent to a nearby room, often called the "freezing room," for tissue preparation, staining, and evaluation. The tissue samples are frozen, cut, stained, and examined using a light microscope by an expert pathologist, who carefully evaluates whether the resection fragment contains cancer cells (positive margins) or does not (negative margins). Intraoperative frozen section analysis has been performed in clinical practice for decades, but it has many problems. Freezing artifacts arise during tissue processing, compromising tissue architecture and cell morphology, thereby complicating pathological interpretation. Moreover, certain tumor cells are very difficult to identify due to their atypical patterns of growth and shape. Molecular approaches would result in highly accurate, and potentially real-time, evaluation of tissue samples. However, to date, no satisfactory devices or techniques have been developed that provide valid molecular evaluation of tissue samples. Summary of the Invention

[0005] In a first embodiment, a method is provided for obtaining a mass spectrometry profile, the method comprising using a probe to apply a fixed or discrete volume of solvent to an assay site (e.g., a tissue site), obtaining a liquid sample using the probe to collect the applied solvent, and subjecting the liquid sample to mass spectrometry analysis. In yet another embodiment, a method is provided for evaluating a tissue sample, the method comprising obtaining multiple liquid samples from multiple tissue sites of a subject, and subjecting the multiple liquid samples to mass spectrometry.

[0006] Yet another embodiment provides an apparatus for obtaining a sample (e.g., from a tissue) for mass spectrometry analysis, the apparatus comprising: a chamber containing a solvent; a pressurized gas supply; a mass spectrometer; and a probe with a reservoir, a first conduit, a second conduit, and a third conduit, the reservoir being in fluid communication with the first conduit, the second conduit, and the third conduit; the first (solvent) conduit being in fluid communication with the chamber; the second (gas) conduit being in fluid communication with the pressurized gas supply; and the third (collection) conduit being in fluid communication with the mass spectrometer. In another aspect, the mass spectrometer is in communication with a computer that provides the sample analysis. In certain aspects, the results of each sample analysis are provided by a visual or audible output from the computer. For example, the results of each sample analysis by the computer may be indicated by differently stained lights being projected or by different frequencies of sound being generated. In some aspects, the mass spectrometer is a mobile mass spectrometer. In another embodiment, the mass spectrometer can be equipped with an uninterruptible power source (e.g., battery power). In a further embodiment, the mass spectrometer is equipped with an inlet that can be closed to maintain a vacuum on the instrument. In yet another embodiment, the mass spectrometer is separated from the probe by a mesh filter (e.g., to prevent contamination).

[0007] In some embodiments, the reservoir is configured to form droplets of the solvent. In certain embodiments, the pressurized gas supply provides gas to the probe at a pressure between 0.1 psig and 5.0 psig. In other embodiments, the pressurized gas supply provides gas to the probe at a pressure between 0.5 psig and 2.5 psig. In some embodiments, the pressurized gas supply provides air to the probe. In other embodiments, the pressurized gas supply provides an inert gas, such as nitrogen or carbon dioxide, to the probe.

[0008] In further embodiments, the apparatus further comprises a pump configured to move the solvent from the chamber through the first conduit. In another embodiment, the apparatus may comprise a first valve configured to control flow from a third conduit to the mass spectrometer. In some embodiments, when the first valve is in an open position, the third conduit is under vacuum. In other embodiments, the apparatus may comprise a second valve configured to control flow of pressurized gas through the second conduit.

[0009] In certain embodiments, the solvent may include water and / or ethanol. In some embodiments, the probe is formed from polydimethylsiloxane (PDMS) and / or polytetrafluoroethylene (PTFE). In some embodiments, the probe is disposable. In certain embodiments, the probe may include a removable collection tip (e.g., removable from the probe). In another embodiment, the probe comprises a tracking device configured to track the position of the probe. In some embodiments, the reservoir has a volume between 1 microliter and 500 microliters, between about 1 microliter and 100 microliters, or between about 2 microliters and 50 microliters. In further embodiments, the reservoir has a volume between 5.0 microliters and 20 microliters.

[0010] In further embodiments, the device may further comprise a control system configured to control the solvent flow from the chamber to the reservoir (e.g., a fixed or discrete volume solvent flow) through a first conduit, the pressurized gas flow from the pressurized gas supply to the reservoir through a second conduit, and the sample flow from the reservoir to the mass spectrometer through a third conduit. In some embodiments, the control system is configured to control the solvent flow at a flow rate between 100 and 5000 microliters per minute (e.g., between 200 and 400 microliters per minute) for a time period between 1 and 3 seconds; to control the pressurized gas flow at a flow rate between 1 and 10 psig for a time period between 10 and 15 seconds; and to control the sample flow for a time period between 10 and 15 seconds. For example, in some embodiments, the control system comprises a trigger or button for initiating the solvent flow. In another embodiment, the control system comprises a pedal (i.e., operable by foot action) for initiating the solvent flow. One skilled in the art will recognize that the length of the first and / or second conduits can be adjusted to suit a particular use of the system. In yet another aspect, the control system is configured to control the flow of solvent (e.g., flow rate for a fixed time period) from the chamber to the reservoir through the first conduit. In another aspect, the apparatus of the embodiment does not include a device for producing ultrasonic or vibrational energy (e.g., in an amount sufficient to disrupt tissue).

[0011] Yet another embodiment provides a method for evaluating a tissue sample from a subject, comprising applying a solvent to a tissue site of the subject, collecting the applied solvent to obtain a liquid sample, and subjecting the sample to mass spectrometry analysis. In certain embodiments, the solvent may be sterile. In some embodiments, the solvent is a pharma-ceutically acceptable formulation. In certain embodiments, the solvent is an aqueous solution. For example, the solvent may be sterile water or may consist essentially of water. In other embodiments, the solvent may comprise about 1% to 5%, 10%, 15%, 20%, 25%, or 30% alcohol. In some embodiments, the solvent comprises 0.1% to 20% alcohol, 1% to 10% alcohol, or 1% to 5% 1% to 10% alcohol (e.g., ethanol). In some cases, the alcohol may be ethanol.

[0012] In some embodiments, applying the solvent to the tissue includes applying a discrete volume of the solvent to the tissue site. In some embodiments, the solvent is applied as a single droplet. In other embodiments, the solvent is applied as a discrete number of droplets, from 1 to 10. In some embodiments, the solvent is applied to the sample from a reservoir via a channel independent of the pressurized gas. In yet other embodiments, the solvent is applied to the sample under low pressure. For example, in some embodiments, the solvent is applied by a mechanical pump such that the solvent is applied to the tissue site with minimal force (e.g., the solvent is moved to a reservoir in contact with the tissue site), thereby exerting minimal pressure (and causing minimal damage) at the tissue site. The low pressure may be less than 100 psig, less than 90 psig, less than 80 psig, less than 70 psig, less than 60 psig, less than 50 psig, or less than 25 psig. In some embodiments, the low pressure is about 0.1 psig to 100 psig, about 0.5 psig to 50 psig, about 0.5 psig to 25 psig, or about 0.1 psig to 10 psig. In certain aspects, the individual volume of the solvent is between about 0.1 and 100 μL, or between about 1 and 50 μL. In another aspect, the applied solvent is withdrawn between 0.1 and 30 seconds after the applying step. In certain aspects, the applied solvent is withdrawn between 1 and 10 seconds (e.g., at least 1, 2, 4, 5, 6, 7, 8, or 9 seconds) after the applying step. In another aspect, the method of the embodiment does not include application of ultrasonic or vibrational energy to the sample or tissue. In some aspects, the tissue site is an internal tissue site to be surgically evaluated.

[0013] In another aspect, the method of the embodiment includes applying a fixed or discrete volume of solvent to the tissue site through a solvent conduit (e.g., using a mechanical pump). In some aspects, the fixed or discrete volume of solvent is moved through the solvent conduit to a reservoir where the solvent is in direct contact with the tissue site (e.g., for 0.5 to 5.0 seconds). In another aspect, recovering the applied solvent includes applying negative pressure to draw the sample into a collection conduit and / or applying gas pressure to push the sample into a collection conduit. In some aspects, the solvent is applied through a solvent conduit separate from the collection conduit. In another aspect where gas pressure is applied to push the sample into the collection conduit, the gas pressure is applied through a gas conduit separate from the solvent conduit and the collection conduit. In certain aspects where gas pressure is applied to push the sample into the collection conduit, the applied gas pressure is less than 100 psig. For example, the gas pressure is preferably less than 10 psig, e.g., 0.1 to 5 psig. In a further aspect, the method of the embodiment is defined as causing no detectable physical damage to the tissue being evaluated.

[0014] In further embodiments, the method may further comprise collecting multiple liquid samples from multiple tissue sites. In some cases, the device (e.g., probe) used to collect the samples is washed between each sample collection. In other embodiments, the device used to collect the samples includes a disposable collection tip (probe) that can be replaced between each sample collection. In certain embodiments, the collection tip may be removable (e.g., can be removed from the device). In certain embodiments, the multiple tissue sites include 2, 3, 4, 5, 6, 7, 8, 9, 10 or more tissue sites in vivo. In another embodiment, the multiple tissue sites surround a surgically excised tissue cut (e.g., ex vivo). In certain embodiments, the excised tissue is a tumor. In some embodiments, the method may be defined as an intraoperative method.

[0015] Yet another embodiment provides a method for identifying the tissue site to be harvested and communicating the location of the site to an operator of the device (probe). Identifying the tissue site to be harvested allows the operator to access the molecular information recorded at the harvested tissue site after harvesting the molecules retrieved from the tissue. At least three types of identification approaches are recognized. In the first approach, an exogenous material is attached to the harvested tissue site identifying the molecular information harvested. In the second approach, the device (probe) is equipped with a tracking sensor / emitter that allows recording and communicating the location of the probe (device) to an imaging device when the molecular information is harvested. In the third approach, the tissue area is modified to allow easy identification of the site after harvesting the tissue molecules. In the first approach, materials that may be attached to the harvested tissue site include, for example, sutures, hemostats, biocompatible polymers that attach to tissue, or RFID chips attached to magnetic beads that allow easy reading and removal. In the second approach type, the probe may include an RF emitter that is part of an RF surgical tracking system, an ultrasound emitter or reflector that is part of an intraoperative US imaging system. In this second approach, when the operator initiates the collection of tissue molecules, a tracking system records the position of the probe in an associated imaging system (e.g., RF, US, CT, MRI) that can communicate with the device. The operator can then later identify any harvested tissue sites by referencing the recorded image(s) that can indicate to the operator the location of the harvest site. In a third approach, the tissue is altered. In this third approach, a laser source in communication with the probe can be used to vaporize or coagulate a pattern into the tissue that identifies the harvest site. Any of these three approaches may be combined. For example, it would be possible to combine approaches 1, 2, and 3. In this case, after harvesting the tissue molecules, an exogenous material is deposited on the tissue site, and the laser patterns the exogenous tissue while the RF sensor records the location of the harvest site and communicates it to the imaging device.

[0016] In yet another aspect, the mass spectrometry comprises ambient ionization MS. In some aspects, subjecting the sample to mass spectrometry analysis may include determining a profile corresponding to the tissue site. In another aspect, the method may further include comparing the profile to a reference profile to identify the tissue site containing diseased tissue. In other aspects, the method also includes excising the tissue site identified as containing diseased tissue. In some aspects, the method is performed using an apparatus according to any of the embodiments and aspects described above.

[0017] In another embodiment, the present invention provides an ex vivo method for evaluating tissue samples, comprising obtaining a plurality of liquid samples from a plurality of tissue sites of a subject, subjecting the plurality of liquid samples to mass spectrometry to obtain a plurality of profiles corresponding to the tissue sites, and comparing the plurality of profiles to a reference profile to identify a tissue site comprising diseased tissue. In a particular aspect, the liquid sample is contained in a solvent. In another aspect, the diseased tissue comprises cancer cells.

[0018] In some aspects of the embodiments, diseased tissue sites for evaluation by the methods and devices of the embodiments contain (or are suspected of containing) cancer cells. Cancer cells that may be evaluated by the embodiments include, but are not limited to, cells or tumor tissue (or tissue surrounding such tumors) from the thyroid, lymph node, bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal, gingiva, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In some embodiments, the cancer is selected from the group consisting of neoplasms, malignant; carcinomas; carcinomas, undifferentiated; giant cell and spindle cell carcinomas; small cell carcinomas; papillary carcinomas; squamous cell carcinomas; lymphoepithelial carcinomas; basal cell carcinomas; pilomatrix carcinomas; transitional cell carcinomas; papillary transitional cell carcinomas; adenocarcinomas; gastrinomas, malignant; cholangiocarcinomas; hepatocellular carcinomas; mixed hepatocellular and cholangiocarcinomas; columnar adenocarcinomas; adenoid cystic carcinomas; adenocarcinomas of adenomatous polyps; adenocarcinomas, familial polyposis; solid tumors; carcinoid tumors, malignant; bronchioloalveolar adenocarcinomas; papillary Adenocarcinoma; chromophobe carcinoma; eosinophilic carcinoma; eosinophilic adenocarcinoma; basophilic carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; Mucoepidermoid carcinoma; Cystic carcinoma; Papillary cystadenocarcinoma; Papillary serous cystadenocarcinoma; Mucinous cystadenocarcinoma; Mucinous carcinoma; Signet ring cell carcinoma; Invasive ductal carcinoma; Medullary carcinoma; Lobular carcinoma; Inflammatory carcinoma; Paget's disease of the breast; Pancreatic acinar cell carcinoma; Adenocarcinoma with metaplasia;Thymoma, malignant;Ovarian stromal tumor, malignant;Theca cell tumor, malignant;Granulosa cell tumor, malignant;Sertoli stromal cell tumor, malignant;Sertoli cell tumor;Leydig cell tumor, malignant;Lipocytoma, malignant;Paraganeuroma, malignant;Extramammary paraganglioma, malignant;Pheochromocytoma;Glomus sarcoma;Malignant melanoma;Amelanotic melanoma;Superficial spreading melanoma;Malignant melanoma associated with giant pigmented nevus;Epithelioid cell melanoma;Blue nevus, malignant;Sarcoma;Fibrosarcoma;Fibrous histiocytoma , malignant;myxosarcoma;liposarcoma;leiomyosarcoma;rhabdomyosarcoma;embryonal rhabdomyosarcoma;alveolar rhabdomyosarcoma;stromal sarcoma;mixed tumor, malignant;mixed Müllerian tumor;nephroblastoma;hepatoblastoma;carcinosarcoma;mesenchymoma, malignant;Brenner tumor, malignant;phyllodes tumor, malignant;synovial sarcoma;mesothelioma, malignant;dysgerminoma;embryonal carcinoma;teratoma, malignant;ovarian goiter, malignant;choriocarcinoma;mesonephroma, malignant;angiosarcoma;hemangioendothelioma, malignant;Kaposi's sarcoma;hemangiopericytoma, malignant;lymphangiosarcoma;The tumor may be osteosarcoma; parosteal osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone; Ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrous astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroglioma; undifferentiated neuroectodermal tumor; cerebellar sarcoma; ganglioblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumor; meningioma, malignant; neurofibrosarcoma; schwannoma, malignant; granular cell tumor, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's disease; or paragranuloma. In another embodiment, the cancer is thyroid cancer, brain cancer (e.g., glioma), prostate cancer, breast cancer (e.g., triple-negative breast cancer), pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), acute myeloid leukemia (AML), melanoma, renal cell carcinoma, or cancer that has metastasized to the lymph nodes;

[0019] As used herein, a "sample" or "liquid sample" may refer to an extract from tissue or other biological sample (e.g., an extract containing proteins and metabolites) obtained by contacting the tissue or biological sample with a solvent according to an embodiment. In some aspects, a sample may be an extract from a non-biological sample, such as the surface of an object (e.g., a forensic sample).

[0020] As used herein, "essentially free" with respect to a particular component is used herein to mean that the particular component is not intentionally incorporated into the composition and / or is present only as a contaminant or in trace amounts. Thus, the total amount of the particular component resulting from any unintentional contamination of the composition is well below 0.01%. Most preferred are compositions in which the amount of the particular component is undetectable by standard analytical methods.

[0021] As used herein, in the specification and claims, "a" or "an" may mean one or more. As used herein, in the specification and claims, when used in conjunction with the word "comprising," "a" or "an" may mean one or more. As used herein, in the specification and claims, "another" or "further" may mean at least a second or more.

[0022] As used herein, in the specification and claims, the terms "conduit" and "tube" are used interchangeably and refer to a structure that can be used to direct the flow of gas or liquid.

[0023] As used herein, in the specification and claims, the term "about" is used to indicate that a value includes the inherent variation of error for the device, method utilized to measure the value, or the variation that exists among study subjects.

[0024] Other objects, features and advantages of the present invention will become apparent from the following detailed description, but it should be understood that the detailed description and specific examples, while indicating particular embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

[0025] The following figures form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these figures in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]

[0026] [Figure 1A-C]FIG. 1A is a schematic of the MasSpec Pen system and operational steps. The pen-sized handheld device is directly integrated into a lab-fabricated mass spectrometer interface with PTFE tubing (or another highly hydrophobic material). The interface houses a pinch valve, a microcontroller, and tubing to connect the system with the mass spectrometer inlet. The system is automatically activated by the user with a foot pedal. FIG. 1B is a schematic of the MasSpec Pen system and operational steps. The MasSpec Pen is designed with a PDMS 3D printed tip and three PTFE conduits that provide an outlet conduit for the inflow water, gas, and droplets to the tip. FIG. 1C is a schematic of the MasSpec Pen system and operational steps. The tip contacts the tissue for analysis, which is designed with three conduits and a solvent reservoir. When the system is activated by use via the pedal (t=0 s), a syringe pump delivers a controlled volume of water to the reservoir. The individual droplets interact with the tissue to extract molecules. In this case, 3 seconds after extraction, the vacuum and gas lines are simultaneously opened to transport the droplets through the tubing from the MasSpec Pen to a mass spectrometer for molecular analysis. [Figure 1D] 1 is a schematic diagram of the MasSpec Pen system and operational steps. [Figure 1E] 1 is a schematic diagram of the MasSpec Pen system and operation steps, showing a close-up of the tip of an example MasSpec Pen. [Figure 1F] 1 is a schematic diagram of the MasSpec Pen system and operation steps, showing a close-up of the tip of an example MasSpec Pen. [Figure 1G] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1H] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1I]1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1J] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1K] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1L] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1M] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1N] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1O] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1P] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment. [Figure 1Q] 1 is a schematic diagram of the MasSpec Pen system and operational steps, and shows an alternative configuration of the system of an embodiment.

[0027] [Figure 2A] Mass spectrum of a mouse brain tissue section from the MasSpec Pen using a Q Exactive Orbitrap mass spectrometer. Mass spectrum of a mouse brain section. [Figure 2B] Mass spectrum of mouse brain tissue section from MasSpec Pen using a Q Exactive Orbitrap mass spectrometer. Total ion chromatography, inset spectrum is from a clean glass slide background (intensity scale of background and mouse brain tissue were set to be the same).

[0028] [Figure 3A] A comparison of mass spectra of biological samples obtained using solvents composed of ethanol:HO (1:20) or ethanol:HO (1:5) is shown. [Figure 3B] Representative negative ion mode MasSpec Pen mass spectra obtained from mouse brain tissue sections using mixtures of water and ethanol in various ratios.

[0029] [Figure 4A] Comparison of mass spectra collected from mouse brain sections using the MasSpec Pen. [Figure 4B] Comparison of mass spectra collected from fresh mouse brain tissue using the MasSpec Pen.

[0030] [Figure 5A] Comparison of mass spectra of breast cancer tissue versus normal tissue for various cancer types. [Figure 5B] Comparison of mass spectra of renal cancer tissue versus normal tissue for various cancer types. [Figure 5C] Comparison of mass spectra of cancerous lymph node tissue versus normal tissue for various cancer types. [Figure 5D] Comparison of mass spectra of ovarian cancer tissue versus normal tissue for various cancer types. [Figure 5E] Comparison of mass spectra of thyroid cancer tissue versus normal tissue for different cancer types.

[0031] [Figure 6A] Mass spectra collected from a MasSpec Pen. [Figure 6B] Mass spectra collected from DESI. [Figure 6C] Comparison between MasSpec Pen and DESI negative ion mode mass spectra obtained from mouse brain tissue sections.

[0032] [Figure 7]Spectrum of thymosin β-4 detected in human tissue under negative ion mode.

[0033] [Figure 8A] Comparison of spectra obtained from fresh normal and cancer thyroid samples. [Figure 8B] MasSpec Pen analysis of papillary thyroid carcinoma and normal tissue sections. Representative negative ion mode MasSpec Pen mass spectra from (top) normal thyroid tissue sections and (bottom) papillary thyroid carcinoma tissue sections are shown. Identification of the most abundant molecular ions is shown. Inset shows optical images of H&E stained tissue sections evaluated by histopathology.

[0034] [Figure 9] PCA of data obtained on human tissue sections, including normal and neoplastic thyroid and breast tissue sections. As observed in the score plot, PC1 and PC3 explain 46.1% of the total variance in the breast tissue dataset, while PC1 and PC2 explain 47.9% of the total variance in the thyroid tissue dataset. Loading plots for each tissue type analyzed are also included.

[0035] [Figure 10A-B] Results of principal component analysis on fresh human tissues. (A) Distinguishing between normal and tumor thyroid gland. (B) Distinguishing between normal and tumor lymph nodes.

[0036] [Figure 11] Molecular information obtained from tissue samples using the MasSpec Pen can aid in the diagnosis of human cancer. A total of 253 patient tissue samples were analyzed, including breast, thyroid, ovarian and lung cancer as well as normal tissue samples. The 3D PCA (PC1, PC2 and PC3) plots show the separation between the obtained cancer and normal mass spectra.

[0037] [Figure 12A-E]Positioning of sample location 1 (Figure 12A), sample location 2 (Figure 12B), sample location 3 (Figure 12C), sample location 4 (Figure 12D), and sample location 5 (Figure 12E).

[0038] [Figure 13A] Mass spectra of sample locations 1–5 over the entire mass range. [Figure 13B] Mass spectra of sample locations 1–5 in the mass range from 500 to 1800. [Figure 13C] Mass spectra of sample points 1–5 in the mass range from 500 to 1000. [Figure 13D] Mass spectra of sample locations 1–5 in the mass range of 785–809. [Figure 13E] Mass spectra of sample points 1–5 in the mass range of 870–920.

[0039] [Figure 14A-C] FIG. 14A: MasSpec Pen analysis of HGSC tissue sample with mixed tissue composition. Optical images show tissue sample analyzed at demarcated sites (1-5) using a 1.5 mm diameter MasSpec Pen. After MasSpec Pen analysis, tissue sample was frozen, sectioned, and H&E stained. Optical image of H&E stained tissue section obtained at site 3 is shown, showing mixed tissue composition including cancer and adjacent normal stromal tissue. FIG. 14B: MasSpec Pen analysis of HGSC tissue sample with mixed tissue composition. MasSpec Pen negative ion mode mass spectra are shown for site 1 (normal stroma), site 3 (mixed normal stroma and cancer), and site 5 (cancer). FIG. 14C: MasSpec Pen analysis of HGSC tissue sample with mixed tissue composition. Pathological diagnosis of the five sites analyzed and Lasso prediction results for this independent data set are shown.

[0040] [Figure 15A]The MasSpec Pen allows for gentle, non-destructive molecular analysis of tissue samples. Optical images show a lung adenocarcinoma tissue sample before, during, and after MasSpec Pen analysis. Magnified photographs of the tissue sample show no macroscopic damage to the tissue area analyzed with the MasSpec Pen. [Figure 15B] The MasSpec Pen allows for gentle, non-destructive molecular analysis of tissue samples. Negative ion mode mass spectra acquired for the analyzed tissue regions are shown, including the identification of the most abundant molecular ions.

[0041] [Figure 16A-B] Figure 16A: In vivo analysis of tumor and normal tissue during surgery in a mouse animal model. Experiments were performed on anesthetized mice. Optical images show before, during, and after MasSpec Pen analysis in animals and in vivo. Figure 16B: In vivo analysis of tumor and normal tissue during surgery in a mouse animal model. Representative negative ion mode mass spectra show distinct molecular profiles from normal and tumor tissues.

[0042] [Figure 17] Representative negative ion mode MasSpec Pen mass spectra obtained using different collection diameters of the MasSpec Pen.

[0043] [Figure 18] Representative positive ion mode mass spectrum from mouse brain tissue. Ions observed at high relative abundance were identified using tandem mass spectrometry as potassium (K+) and sodium (Na+) adducts of glycerophosphocholine and diacylglyceride lipids, as annotated in the mass spectrum.

[0044] [Figure 19] Representative negative ion mode MasSpec Pen mass spectra from HGSC tissue samples containing areas of normal and cancerous tissue.

[0045] [Figure 20] Optical images of H&E stained tissue sections from the same areas after in vivo analysis and after MasSpec Pen analysis.

[0046] [Figure 21] Comparison between MasSpec Pen negative ion mode mass spectra obtained in vivo and ex vivo of the same tumor sample in a mouse model.

[0047] [Figure 22] Representative negative ion mode mass spectra obtained from mouse brain tissue sections using different extraction times: 5 s, 3 s, and 1 s. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] I. This Present Embodiment In certain aspects, the present application provides methods and devices for molecular evaluation of samples, such as tissue samples. In certain aspects, the methods can be used to evaluate multiple tissue sites during surgery (or biopsy) of tissue. This feature allows for precise identification of diseased tissue (e.g., tissue sites harboring cancer cells) in "real time," allowing the surgeon to more precisely address only the diseased tissue versus the surrounding normal tissue. In certain aspects, the methods disclosed herein can include delivery of a fixed or discrete volume of solvent to a tissue site, followed by collection of a liquid sample from the site and analysis of the liquid sample by mass spectrometry. Importantly, the solvent is applied at low pressure as discrete droplets, rather than being applied as a high pressure spray. These methods allow for precise collection of samples from different tissue sites while avoiding damage to the tissue being evaluated. Mass spectrometry profiles obtained from the collected samples allow for differentiation of diseased tissue versus normal tissue sites. The methods can be repeated at multiple sites of interest to localize molecular changes (e.g., in the tissue) with great precision. Importantly, the sample profiles could be distinguished without the use of an ionization source. Thus, while the methods of the embodiments could be used with an ionization source, the use of such an ionization source is not necessary. These techniques can allow for the evaluation of multiple tissue sites over a short time span, thereby allowing the boundary between diseased and normal tissue to be assessed with great accuracy.

[0049] In some embodiments, the methods detailed herein can be used to collect and analyze samples from a wide range of sources, for example, the methods can be used to evaluate forensic, agricultural, drugs of abuse, pharmaceutical, and / or oil / petroleum samples.

[0050] In some aspects, the materials (PDMS and PTFE) and solvents (e.g., water-only solvent) used in the device of the embodiments are biologically compatible so that they can be used in surgery for real-time analysis. Furthermore, the devices can be made extremely small, so that they can be handheld or integrated into a robotic surgery system such as the Da Vinci surgery system (e.g., in an automated system). Thus, many areas of a human body cavity can be rapidly sampled during surgery and analyzed (e.g., by using a database of molecular signatures and machine learning algorithms). Thus, diagnostic results for each sampled area can be provided in real time. Exemplary devices for use in these methods are detailed below.

[0051] Referring first to FIG. ID, an apparatus 100 for sampling tissue for mass spectrometry analysis is shown. In this embodiment, the apparatus 100 includes a probe 110, a chamber 120 containing a solvent, a pressurized gas supply 130, and a mass spectrometer 140. In some embodiments, the probe is included in a housing (e.g., to provide a grip in the case of a handheld device). In another embodiment, the housing may include a switch function (e.g., a trigger, button, or pedal) that can be used to control fluid and / or gas flow through the probe. In some embodiments, the probe is constructed from materials including PDMS and / or PTFE. In some embodiments, the probe is fabricated by a 3D printing process.

[0052] Figure 1E shows a more detailed cross-sectional view of probe 110, showing probe 110 with first conduit 111, second conduit 112, third conduit 113 and reservoir 115. In the embodiment shown, first conduit 111 is in fluid communication with chamber 120, second conduit 112 is in fluid communication with pressurized gas supply 130, and third conduit 113 is in fluid communication with mass spectrometer 140. Figure 1F provides a further cross-sectional view of the probe with dimensions for certain embodiments.

[0053] Of course, in certain embodiments, each of the conduits 111, 112, and 113 (which may be of any desired length) may comprise separate components. For example, each portion of the conduits within the probe 110 may be formed as an integral channel during the manufacturing process of the probe 110. Additionally, each portion of the conduits between the probe 110 and the chamber 120, the pressurized gas supply 130, and the mass spectrometer 140 may be tubing or other components suitable for providing fluid flow.

[0054] In this embodiment, the apparatus 100 may include a pump 125 configured to move the solvent from the chamber 120 to the first conduit 111 and to the reservoir 115. In the embodiment shown, the apparatus 100 may also include a first valve 121 configured to control the flow of sample from the reservoir 115 through the third conduit 113 to the mass spectrometer 140. The apparatus 100 may also include a second valve 122 configured to control the flow of pressurized gas through the second conduit 112 to the reservoir 115.

[0055] The control system 160 can be configured to control the operating parameters of the apparatus 100. For example, the control system 160 can be configured to control the flow of solvent from the chamber 120 to the reservoir 115 through the first conduit 111 by controlling the operation of the pump 125. Additionally, the control system 160 can be configured to control the flow of sample from the reservoir 115 to the mass spectrometer 140 by controlling the opening and closing of the first valve 121. The control system 160 can be further configured to control the flow of pressurized gas from the pressurized gas container 130 to the reservoir 115 by controlling the opening and closing of the second valve 122.

[0056] During operation of the device 100, a user can position the probe 110 so that the reservoir 115 is located at the sample site 150. The control system 160 can operate the pump 125 for a particular time to move a desired volume of solvent from the chamber 120 to the reservoir 115 via the first conduit 111. In an exemplary embodiment, the solvent in the chamber 120 can aid in the efficient extraction of molecules from the tissue sample site 150 for analysis.

[0057] Additionally, the control system 160 can provide a specific time between the operation of the pump 125 and the opening of the first valve 121. This allows for suction from the mass spectrometer 140 (or a separate auxiliary suction system) to draw sample material (e.g., molecules from the tissue sample site 150) from the reservoir 115 via the third conduit 113 into the mass spectrometer 140.

[0058] When the first valve 121 is opened, the control system 160 also opens the second valve 122 to allow an inert gas (e.g., N2 or CO2) to be transferred from the pressurized gas supply 130 to the reservoir 115 via the second conduit 112. The inert gas can assist in drying the sample tissue prior to analysis and also prevent a solvent gap in the first conduit 111 (e.g., as a result of the suction drawn by the mass spectrometer 140 when the reservoir 115 contacts the sample site 150). The inert gas can also assist in solvent transport from the sample site 150 to the mass spectrometer 140 through the third conduit 113.

[0059] Control system 160 may include software and hardware suitable for operating the various components of device 100. Particular embodiments of the various components shown in the schematic diagram of Figure 1 are illustrated in the examples described below, including the section entitled Example 1.

[0060] FIG. 1G shows an embodiment of the apparatus 100 similar to the embodiment shown in the previous FIG. 1D. However, in the embodiment of FIG. 1G, the apparatus 100 further comprises a pump 141 in fluid communication with the conduit 113. In certain embodiments, the pump 141 may be an external vacuum pump operable to increase the velocity of the sample portion through the conduit 113 to the mass spectrometer. It will be appreciated that the components of the apparatus 100 described in the previous embodiment operate in an equivalent manner in this embodiment (and the embodiment described next). For clarity, not all components are numbered in each of the figures. Furthermore, aspects of operation of components equivalent to components of the previously described embodiment will not be repeated in the discussion of this or the next embodiment.

[0061] FIG. 1H shows another embodiment of the device 100 similar to the embodiment described above, but also including a valve 142 in fluid communication with the conduit 113, a waste container 143, and a pump 144. In certain embodiments, the valve 142 can be used to divert a solvent or other cleaning solution from the conduit 113 to the waste container 143 during a cleaning step. The waste container 143 can be emptied by operation of the pump 144. In an exemplary embodiment, cleaning or washing steps using water, ethanol, mixtures of water and ethanol in any ratio, as well as other solvents can be used at any stage of the sample analysis to reduce the effects of carryover. In certain embodiments, the probe 110 can also be replaced between each use. Additionally, the probe 110 can be inserted into a vial containing a solvent for a washing step using gas (aeration) to aid in cleaning before or after the automated washing step. Other washing methods can also be used, including wiping with a sterilizing solution. For example, a particular embodiment may use the following cleaning procedure: 1. Replace probe; 2. Wash with a 50 / 50 ethanol / water solution; 3. Wash with 100% ethanol.

[0062] 1I illustrates another embodiment of the apparatus 100 similar to the previously described embodiment, but also including a heating element 145 in the conduit 113. In certain embodiments, the heating element 145 is configured as a heating wire that may be wrapped around the conduit 113. Other embodiments may include different heating element configurations, including, for example, a ceramic heater. The conduit 113 may be heated to improve water or solvent transport to the mass spectrometer 140 as well as to assist in ionization in any of the example embodiments described herein. Heating may be performed throughout the entire conduit system or at specific locations.

[0063] Figure 1J illustrates an embodiment of apparatus 100 that combines features of the previously described embodiments. In particular, the embodiment illustrated in this figure includes a heating element 145 and a pump 141 in conduit 113. Aspects of operation of heating element 145 and pump 141 have been previously discussed in the discussion of Figures 1I and 1G, respectively, and will not be repeated here for the sake of brevity.

[0064] FIG. 1K shows an embodiment of the apparatus 100 similar to the previously described embodiment, but also including an ionization device 146 for forming a spray proximal to the inlet to the mass spectrometer 140. In certain embodiments, the ionization device 146 may be, for example, an electrospray ionization (ESI) device, a nano ESI device, or an atmospheric pressure chemical ionization (APCI) device. In certain embodiments, the conduit 113 is not directly coupled to the mass spectrometer 140, and a venturi device 147 can be used to transport droplets of the sample 150 to the interface of the ionization device 146 and the mass spectrometer 140. A mass spectrometry profile is shown in FIG. 1L of an embodiment of the apparatus 100 including a venturi device. As shown in FIG. 1L, the profile obtained is similar to an embodiment in which the conduit 113 is directly coupled to the inlet of the mass spectrometer 140.

[0065] Referring now to FIG. 1M, an embodiment of the apparatus 100 includes an external pump 141 as shown (as previously shown and described in FIG. 1G) as well as an ionization device 146 and a venturi device 147 (as previously shown and described in FIG. 1K).

[0066] As shown in the embodiment of FIG. 1N, the embodiment of the apparatus 100 includes a heating element 145 as shown (as previously shown and described in FIG. 1I) as well as an ionization device 146 and a venturi device 147 (as previously shown and described in FIG. 1K).

[0067] As shown in the embodiment of Figure 1O, the embodiment of the apparatus 100 includes a heating element 145 as shown (as previously shown and described in Figure 1I) as well as an ionizing device 146 and a venturi device 147 (as previously shown and described in Figure 1K). Additionally, this embodiment also includes an external pump 141 (as previously shown and described in Figure 1G).

[0068] As shown in the embodiment of Figure 1P, the embodiment of apparatus 100 includes valve 142, waste container 143, and pump 144 (as previously shown and described in Figure 1H). Additionally, this embodiment also includes ionization device 146 and venturi device 147 as shown (as previously shown and described in Figure 1K).

[0069] As shown in the embodiment of FIG. 1Q, the embodiment of apparatus 100 includes valve 142, waste container 143, and pump 144 (as previously shown and described in FIG. 1H). Additionally, this embodiment also includes ionization device 146 as shown, and venturi device 147 (as previously shown and described in FIG. 1K). This embodiment further includes heating element 145 (as previously shown and described in FIG. 1I).

[0070] II. Assay Methods In some embodiments, the present disclosure provides a method for determining the presence of diseased tissue (e.g., tumor tissue) or finding molecular signatures of biological samples by identifying unique patterns in mass spectrometry profiles. Biological samples for analysis can be animals, plants, or any material (living or non-living) that has been in contact with a biomolecule or organism. Biological samples can be taken in vivo (e.g., during surgery) or ex vivo.

[0071] The profile obtained by the method of the embodiment may correspond to, for example, proteins, metabolites, or lipids from the biological sample or tissue site to be analyzed.These patterns may be determined by measuring the presence of specific ions using mass spectrometry.Some non-limiting examples of ionization methods that can be coupled with this device include chemical ionization, laser ionization, atmospheric pressure chemical ionization, electron ionization, fast atom bombardment, electrospray ionization, and thermal ionization.Further ionization methods include inductively coupled plasma sources, photoionization, glow discharge, field desorption, thermospray, silicon-based desorption / ionization, real-time direct analysis, secondary ion mass spectrometry, spark ionization, and thermal ionization.

[0072] In particular, the method may be applied to or coupled with methods for obtaining mass spectral data such as ambient ionization sources or extractive ambient ionization sources, which in this case are methods involving ionization kinetically following a liquid extraction process. Some non-limiting examples of extractive ambient ionization sources include airflow assisted desorption electrospray ionization (AFADESI), direct analysis in real time (DART), desorption electrospray ionization (DESI), desorption ionization by charge exchange (DICE), electrode assisted desorption electrospray ionization (EADESI), electrospray laser desorption ionization (ELDI), electrostatic spray ionization (ESTASI), jet desorption electrospray ionization (JeDI), laser assisted desorption electrospray ionization (LADESI), laser desorption electrospray ionization (LDESI), matrix assisted laser desorption electrospray ionization (MALDESI), nanospray desorption electrospray ionization (nano-DESI), or transmission desorption electrospray ionization (TM-DESI).

[0073] As with many mass spectrometry methods, ionization efficiency can be optimized by altering collection or solvent conditions such as solvent components, pH, gas flow rate, applied voltage, and other aspects that affect the ionization of the sample solution. In particular, the method contemplates the use of a solvent or solution that is compatible with the human problem. Some non-limiting examples of solvents that can be used as ionization solvents include water, ethanol, methanol, acetonitrile, dimethylformamide, acids, or mixtures thereof. In some embodiments, the method contemplates a mixture of acetonitrile and dimethylformamide. The amount of acetonitrile and dimethylformamide can also be varied to increase the extraction of analytes from the sample as well as to increase the ionization and volatility of the sample. In some embodiments, the composition comprises about 5:1 (v / v) dimethylformamide:acetonitrile to about 1:5 (v / v) dimethylformamide:acetonitrile, e.g., 1:1 (v / v) dimethylformamide:acetonitrile. However, in preferred embodiments, the solvent for use with the embodiments is a pharma- ceutically acceptable solvent, such as sterile water or a buffered aqueous solution. EXAMPLES

[0074] III. Examples The following examples are included to demonstrate preferred embodiments of the invention. It should be recognized by those of skill in the art that the techniques disclosed in the examples which follow are techniques discovered by the inventors to function well in the practice of the invention and therefore can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

[0075] Example 1: Smart MasSpec Pen Design The MasSpec Pen (Figure 1A) was developed as an automated, biocompatible, handheld sampling probe that allows gentle, time- and volume-controlled extraction of molecules from tissue samples using discrete droplets of water. Several prototypes of the system were designed with the goals of minimizing tissue damage, maximizing extraction of tissue analytes, and maximizing solvent transfer to the mass spectrometer.

[0076] The developed system consists of three main parts: 1) a syringe pump programmed to deliver discrete solvent volumes using a controlled flow rate; 2) tubing integrated with a two-way pinch valve for controlled solvent transport; and 3) a probe tip used for direct sampling of biological tissue. Several iterations of the system were investigated and optimized with the end goals of minimizing tissue damage, maximizing extraction of tissue specimens, and maximizing solvent delivery to the mass spectrometer. Figure 1A shows a schematic diagram of one example of an apparatus with a Diagnostic Pen (MasSpec Pen) device for analyzing biological tissue.

[0077] The optimized system includes three main components: 1) a syringe pump programmed to deliver a defined volume of water (4-10 µL) to the sampling probe; 2) a conduit of small diameter (ID 800 µm) polytetrafluoroethylene (PTFE) tubing integrated into a fast (8 ms) two-way pinch valve for controlled solvent transport from the pump to the tissue and from the tissue to the mass spectrometer; 3) a pen-sized handheld probe for direct sampling of biological tissue.

[0078] The main component of the pen-sized handheld probe is a 3D printed polydimethylsiloxane (PDMS) tip (Figure 1B) where the solvent is retained during interaction with the tissue. The tip is manufactured using 3D printing and made from biologically compatible polydimethylsiloxane (PDMS). The tip is designed with three main ports: a port for the inflow (solvent) conduit system (tube 111 or conduit 1), a central port for gas (N2, CO2 or air) delivery (tube 112 or conduit 2), and an outflow port (tube 113 or conduit 3) that transports molecular components in droplets from the tissue to the mass spectrometer. At the probe tip, all ports merge into a small reservoir. In this reservoir, one droplet is retained and exposed to the tissue sample for a controlled time (3 s), allowing efficient analyte extraction. The diameter of the reservoir determines the volume of solvent exposed to the tissue as well as the spatial resolution of the device. Using current tooling, the MasSpec Pen tip was designed with collection sizes ranging from 1.5 mm to 5.0 mm, determined by the reservoir diameter. With a reservoir diameter of 2.77 mm, 10 μL of solvent volume is held in the reservoir and in contact with the tissue sample for a defined time, while with a diameter of 1.5 mm, 4.4 μL is held in the reservoir. After an extraction time of 3 s, the MasSpec Pen is removed from the tissue. Conduit 3 is opened, which allows for vacuum extraction of the droplet into the mass spectrometer, while positive pressure is provided from low pressure gas delivery (<10 psi) through conduit 2, followed by a flushing step to clean the system. Contact times between the droplet and the tissue sample of 1, 3 and 5 seconds were evaluated (FIG. 22). A contact time of 3 seconds was selected for all experiments, as it allowed ease of operation by the user and yielded mass spectra of sufficient total ion intensity. The gas provided by the second tube does not participate in the extraction process, but is instead used to prevent collapse of the system due to the applied vacuum and to assist in solvent transport from the tissue to the mass spectrometer. Similarly, a flush step for extraction of biomolecules from the tissue is not used since there is no contact with the tissue during this period.Conduit 3 is directly connected to the transfer tube of the high mass resolution Orbitrap mass spectrometer so that the negative pressure of the mass spectrometer vacuum system moves the droplets from the reservoir to the mass spectrometer for ionization and mass analysis. Although a variety of connections and ionization methods could be interfaced to our system, this setup simplifies the operational steps and eliminates the use of an ionization source. A tubing length of 1.5 meters was utilized for all conduits to allow the operator the freedom to use the device handheld without geometric or spatial constraints.

[0079] The three conduits used are made from polytetrafluoroethylene (PTFE), which is also biologically compatible. Tube 111 is used to deliver solvent from the syringe pump to the probe tip. Tube 112 is used in some cases to deliver inert gas (N2 or CO2) to the probe tip. The gas serves three main purposes: 1) drying the tissue prior to analysis; 2) preventing a solvent gap in tube 111 due to the mass spectrometer vacuum when the reservoir is closed by contacting it with the tissue sample; 2) assisting in the transport of solvent from the tissue to the mass spectrometer through tube 113. However, in some situations, the use of gas is not necessary. Tube 113 is connected directly to the inlet of the mass spectrometer so that the positive pressure of the mass spectrometer vacuum system is used to force droplets from the reservoir to the mass spectrometer inlet for ionization.

[0080] The time events involved in the device operation are automated and precisely controlled by the software that communicates with the Arduino system and the two two-way pinch valves. All pinch valves are closed until the process is started, then: 1. A pulse is sent to the pump at 300 μL / min to inject solvent for 2 seconds and shut off to form a 10 μL droplet that fills the MasSpec Pen reservoir; 2. Tubes 112 and 113 are closed, allowing the solvent in the reservoir to interact with the tissue for 3 seconds to extract molecules; 3. The pinch valves controlling tubes 112 and 113 are simultaneously opened, allowing the droplet to move to the mass spectrometer for ionization and molecular analysis; 4. A pulse is sent to the pump to inject solvent for another 12 seconds and shut off to completely push all extracted molecules to the mass spectrometer; 5. Tubes 112 and 113 are left open for another 20 seconds to allow all the solvent in tube 113 to go to the mass spectrometry. The total analysis time is 37 seconds.

[0081] The tip design, using three conduits and fast-acting pinch valves, allows for precise control of droplet movement and has demonstrated excellent performance and robustness. The entire process from sample collection to mass spectrum acquisition is completed in under 10 seconds and is fully automated using an Arduino microcontroller, so that each acquisition and analysis is individually actuated by a single click using a foot pedal. The system automation ensures that each solvent droplet is delivered to the inlet separately, resulting in several mass spectra that are averaged for the final molecular profile of the sample. Furthermore, the controlled droplet delivery allows the mass spectrometer to operate without any apparent performance degradation. After each use, the MasSpec Pen can be cleaned by a fast automated cleaning wash or by replacing the disposable tip if residue is identified.

[0082] Example 2: Molecular Profiles and Analysis The system described herein operates by directly connecting a collection conduit with the mass spectrometer inlet to transport the analyte-containing solvent to the mass spectrometer for molecular analysis. This setup greatly simplifies the operational details and eliminates the use of an ionization source. After the probe interacts with the tissue, the solvent is then transported to the mass spectrometer and directly injected without the need for an additional ionization source. The mass spectrometer operates without any impact on its performance because the system is fully automated such that each 10 μL solvent droplet is delivered separately to the inlet. A wealth of molecular information similar to that observed with other solvent extraction ambient ionization techniques such as desorption electrospray ionization is obtained with this approach. The ionization mechanism may be similar to that of inlet ionization. For the inlet ionization method, ionization occurs in the pressure drop region of the inlet between atmospheric pressure and vacuum. Several solvent systems can be used in the device. In this example, mixtures of ethanol and water in various ratios were also investigated with similar results, but water was used as the only solvent to ensure the full biocompatibility of the device. To demonstrate, these samples were analyzed after extraction with solvents composed of 5:1 and 20:1 (HO:EtOH) and found that EtOH aided in the extraction of more PE lipids, such as PE(40:6) (m / z 790.539) and PE(38:4) (m / z 766.540) (see results in Figure 3).

[0083] The effectiveness of the MasSpec Pen in obtaining molecular information was tested by analyzing thin tissue sections and small pieces of tissue samples. First, 16 μm thick tissue sections were analyzed on standard tissue slides following the automated operating steps described above for the MasSpec Pen using pure water as the solvent. Several probe tips with different reservoir diameters of the MasSpec Pen were tested to obtain mass spectra characteristic of lipid species of mixed composition for mouse brain tissue gray matter, white matter, or larger collection sizes. Figure 2 shows a representative mass spectrum obtained in negative ion mode using a 2.7 mm pen tip from a gray matter region of a mouse brain tissue section, and a representative background mass spectrum obtained from a region of a glass slide (no sample). Several diameters of the MasSpec Pen were tested, obtaining similar mass spectral profiles, with increased total ion counts observed for larger pen tip diameters (Figure 17).

[0084] Figure 2B shows the total ion chromatograms obtained during the entire analysis period. At 0.5 min (see inset graph in Figure 2B), a background mass spectrum was obtained by contacting with pure glass. As can be seen from the mass spectrum, a very clean background signal was obtained in this mass spectrum. At 3.4 min (Figure 2A), the MasSpec Pen was applied to the mouse brain tissue section following the same procedure as described above. Notably, a rich molecular profile was observed. Lipid signals commonly detected using ambient ionization mass spectrometry of biological tissues were observed with high relative intensity in the negative ion mode mass spectrum and included fatty acids (FA), ceramides (Cer), glycerophosphoinositols (PI), glycerophosphoethanolamines (PE), glycerophosphoserines (PS) and sterol lipids (ST). Primary and secondary endogenous metabolites were also observed in the mass spectrum. In positive ion mode, diradilglycerol (DG), glycerophosphocholine (PC) and sphingophospholipids (SM) were also detected. A high-resolution powder mass analyzer (resolution set at 140,000) was used to identify the majority of the lipids in the spectrum.

[0085] Negative ion mode mass spectra obtained from grey matter regions of mouse brain tissue sections showed a wealth of molecular information, including a variety of ions corresponding to deprotonated or chlorine adducts of lipid species commonly detected from biological tissues using solvent-based ambient ionization MS techniques. Peaks of high relative abundance were identified as fatty acids (FA) at m / z 120-350, sphingolipids such as sulfatides at m / z 700-1100 and chlorine adducts of ceramide (Cer) at m / z 500-700, as well as glycerophosphoinositols (PI), glycerophosphoethanolamine (PE), glycerophosphoserine (PS) and divalent cardiolipin (CL) at m / z 700-1100. In the higher mass range of m / z 1100-1800, GL dimers and singly charged CL were observed. Various peaks tentatively identified as small metabolites, including glutamine at m / z 145.061, glutamate at m / z 146.045, N-acetylaspartic acid at m / z 174.041, and a chlorine adduct of hexose at m / z 215.033, were detected in the lower mass range of m / z 120–250 based on the high mass accuracy measurements and tandem mass spectrometry data (Table 1). Importantly, negative ion mode mass spectra (RSD=9.3%, n=9) obtained from the gray matter of different tissue sections of the same mouse brain were reproducible comparable to those reported using the same methodology for DESI-MSI (RSD=8.0%, n=5). In positive ion mode, the mass spectra obtained showed commonly observed molecular species of high relative abundance that were identified as diacylglycerol (DG), PE, and glycerophosphocholine (PC) (Figure 18). Tentative assignments were made using high mass accuracy measurements, as well as tandem MS analysis, when sufficient intensity of the fragment ions was achieved for structural interpretation. Mass errors and m / z of fragment ions obtained by tandem MS experiments are listed in Tables 1, 2, 3, 4, and 5 for all species identified throughout the manuscript.Furthermore, double bond isomerism in the FA chains of complex lipids complicates precise structural assignment, which is why FA chains are tentatively assigned to lipid species (Dill et al., Analytical and Bioanalytical Chemistry, 12, 2011).

[0086] MasSpec Pen spectra were compared with DESI spectra obtained under similar MS parameters but using the commonly applied acetonitrile and dimethylformamide solvent system due to its high efficiency for the extraction of lipids from biological tissues. Interestingly, in negative ion mode, the spectrum from MasSpec Pen using water as the extraction solvent shared abundant species from m / z 500 to m / z 1800 with the spectrum from DESI using ACN and DMF, with a slightly higher ratio of PE lipids such as PE(40:6) (m / z 790.539) and PE(38:4) (m / z 766.539). Figure 6A-B shows that PI(38:4) (m / z 885.550) and PS(38:6) (m / z 834.529) were the main peaks in both spectra from MasSpec Pen and DESI. Additionally, a group of higher m / z ions was observed in the spectrum in the mass range from m / z 1500 to m / z 1600, which were tentatively assigned to be monocharged cardiolipin (CL) and / or glycerophospholipid dimers.

[0087] Further analysis compared the molecular species detected in negative ion mode with those observed in DESI mass spectra obtained from consecutive tissue sections of the same mouse brain using water as the solvent and similar experimental conditions. The mass spectra obtained using the MasSpec Pen and DESI were similar with a calculated cosine similarity of 0.9, sharing many molecular species with similar relative abundances and signal-to-noise (S / N) ratios (Figure 6C). Other solvent systems, including mixtures of water and ethanol in various ratios, were also investigated as solvent systems for the MasSpec Pen. The mass spectra obtained showed lipid species similar to those observed in the mass spectra obtained using pure water, albeit at different relative abundances (Figure 3B). Therefore, to ensure full biocompatibility of the device, water was selected as the solvent for all the following MasSpec Pen experiments performed.

[0088] To evaluate the performance of the system, sequential analyses were performed on the same and different tissue sections, demonstrating that the system is highly reproducible within and between different samples.

[0089] Molecular Analysis of Human Cancer and Normal Tissue Sections. Ambient ionization mass spectrometry has been widely investigated for molecular diagnostics of human cancer tissues. To test the ability of the MasSpec Pen system described herein to distinguish between normal and tumor samples, 62 human tissue samples of five different tissue types were analyzed, including breast, kidney, lymph node, thyroid, and ovary. Mass spectra acquired in negative ion mode using water as the solvent system for each tissue type showed molecular ions commonly observed by DESI-MS along with high relative abundance of metabolites and lipids. Principal component analysis (PCA) was utilized to statistically evaluate the performance of the MasSpec Pen in the inter- and intra-species analysis of human samples. It should be noted that the first three components, which together contain more than 85% of the total variance, are used in this study. As can be seen from Figure 9A-B, normal thyroid and kidney tissues were well differentiated from tumor tissues. Surprisingly, during the analysis of human tissue sections under negative ion mode, a series of multiply charged species were detected and identified as thymosin β-4 by high mass accuracy measurements and tandem mass spectrometry analysis (Figure 7). Representative spectra of each sample are shown in Figure 5. Remarkably, the molecular profiles obtained from human normal thyroid and cancer tissues show distinct molecular patterns that are useful for the diagnosis of disease states. Similar results were obtained for all other cancer tissues analyzed.

[0090] The capabilities of the MasSpec Pen were tested by analyzing 20 thin tissue sections of normal and tumoral human breast (n=5 normal breast, n=5 ductal carcinoma) and thyroid (n=5 normal thyroid, n=4 papillary thyroid carcinoma, and n=1 follicular thyroid adenoma) tissues. Mass spectra for each tissue type acquired in negative ion mode showed abundant molecular ions commonly observed from human tissues by DESI-MSI, along with high relative abundance of metabolites, fatty acids, and complex lipids. For example, mass spectra obtained on papillary thyroid carcinoma tissue sections showed a variety of doubly charged CLs, as well as lipid species previously identified as diagnostic markers by DESI-MSI (Zhang et al., Cancer Research, 76, 2016), including other glycerophospholipids such as PI(38:4) (m / z 885.550), PI(36:4) (m / z 857.518), PE(38:4) (m / z 766.539), and PE(36:2) (m / z 742.539) (Table 2). A distinct mass spectral profile was obtained for normal thyroid tissue sections, which showed high relative abundance of m / z 126.904 identified as iodine, m / z 145.050 identified as glutamine, m / z 175.024 identified as ascorbic acid, m / z 822.472 tentatively assigned as C36H78O9N3I, and m / z 885.551 identified as PI(38:4) (Figure 8B). Interestingly, a series of multiply charged molecular ions of different charge states (z), including m / z 991.091 (z=-5), m / z 1239.113 (z=-4), and m / z 1652.484 (z=-3), were detected in the mass spectra obtained from all tissue sections analyzed. These ions were tentatively identified as the protein thymosin β-4 in different charge states based on high mass accuracy measurements (Figure 7 and Table 1). Notably, principal component analysis (PCA) performed on the data from the analyzed human tissue sections showed separation between tumor and normal tissue (Figure 9).

[0091] Molecular analysis of fresh tissue samples. The MasSpec Pen device was designed to work on fresh tissue samples regardless of morphology. Fresh mouse brain tissue was used first to test the device for fresh tissue analysis. No significant differences were identified in the spectra obtained from mouse brain tissue sections or fresh brain tissue. Figures 4A-4B show nearly identical mass spectrometry patterns of mouse brain fresh tissue and tissue sections, indicating that the extraction process from the MasSpec Pen works similarly for different sample preparation steps. Two types of fresh human samples were then further analyzed: thyroid and lymph node. The spectra of normal and cancerous thyroid fresh tissue samples are shown in Figure 8.

[0092] It should be noted that all frozen samples obtained from the tissue bank were properly stored in a freezer below -80 °C and thawed at room temperature before use. Data collected from fresh human samples were also processed by PCA. PCA of the recorded spectra shows clear differences between normal and tumor samples (Figures 10A-10B). Thus, it is established that the MasSpec Pen could be utilized to distinguish fresh normal and diseased samples. It should be noted that no damage to the tissue due to the sample collection process was observed.

[0093] Table 1: Data obtained from mouse brain tissue for the identification of selected negative ion mode molecular ions. [Table 1]

[0094] Table 2. Data obtained from human thyroid tissue for the identification of selected negative ion mode molecular ions. [Table 2]

[0095] Table 3. Data obtained from human ovarian tissue for the identification of selected negative ion mode molecular ions. [Table 3]

[0096] Table 4. Data obtained from human lung tissue for the identification of selected negative ion mode molecular ions. [Table 4]

[0097] Table 5. Data obtained from human breast tissue for the identification of selected negative ion mode molecular ions. [Table 5]

[0098] Table 6. Patient demographics for the 253 human tissue samples used in this study. [Table 6]

[0099] Materials and Methods. Mass spectrometer. A Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific, San Jose, CA) was used. A full scan was performed in the range of m / z 120-1800, and other mass spectrometry parameters were as follows: resolution 140000, microscan 2, maximum injection time 300 ms, capillary temperature 350 °C, and S-lens RF level 100.

[0100] Biological Tissues. Wild-type mouse brain was purchased from Bioreclamation IVT. Sixty-two frozen human tissue samples, including breast, thyroid, lymph node, ovary, and kidney, were obtained from the Cooperative Human Tissue Network and the Baylor College Tissue Bank. Samples were stored in a -80°C freezer. Tissue slides were cut at 16 μm using a CryoStar™ NX50 cryostat. Frozen tissue samples were thawed at room temperature before use.

[0101] Statistical analysis. Principal component analysis (PCA) was performed using IBM SPSS Statistics 22.0 (IBM Corporation, Armonk, NY, USA) to reveal patterns in the data. The analysis was performed directly using the raw data. The top 10 peaks with relative intensity in the m / z range of 700–900 were used for PCA. In general, the first three components, which contained more than 85% of the total variance in all three components, were used in the present results.

[0102] Example 3: System automation for handheld and laparoscopic use Since all materials (PDMS and PTFE) as well as the solvent (only water) used in the MasSpec Pen design are biologically compatible, this system has a high potential to be used in surgery in a handheld fashion for real-time analysis. Besides, the small dimensions of the device even allow it to be integrated into a robotic surgery system such as the Da Vinci surgery system through an accessory port or one of its robotic arms. Several areas of the human body cavity can be rapidly sampled during surgery and analyzed by using a database of molecular signatures and machine learning algorithms. Thus, diagnostic results for each sampled area are obtained in real time. This system can be widely used for a wide variety of oncological and other surgical procedures (such as endometriosis) where real-time characterization and diagnosis of tissue is required.

[0103] Example 4: Predictive Analysis of Tissue Samples The MasSpec Pen design was used to analyze tissue samples from patients with breast, lung, ovarian, or thyroid cancer along with normal tissue samples. Prior to analyzing these samples, they were processed by rounding the mass-to-charge ratio (m / z) to the nearest 0.01 and normalizing the total ion chromatogram (TIC). All background m / z peaks and peaks that appeared in less than 10% of the patient samples were also removed. The full mass range was used for the analysis. The trained classifier was a lasso logistic regression model. The overall performance results for all classifiers for tissue samples analyzed for the presence of cancer are shown in Table 7. The overall results have an accuracy of 96.3%, a sensitivity of 96.4%, and a specificity of 96.2%. Table 7: Tissue sample predictions for all normal vs. all cancer actual calls * [Table 7]

[0104] For the tissue samples analyzed for the presence of lung cancer, Table 8 shows the mass-to-charge values ​​(m / z) used to identify the tissue samples along with the association coefficients for that particular value. Table 8: Mass-to-charge values ​​(m / z) and coefficients for lung cancer relative to normal lung vs. lung cancer [Table 8]

[0105] Table 9 shows the resolution rate and classification of each sample, with the actual (histological) determination in the rows and the predicted values ​​in the columns. For cancer tissue samples, samples were identified with an accuracy of 96.8%, a sensitivity of 97.9%, a specificity of 95.7% and an AUC of 0.97. Table 9: Tissue sample predictions versus actual outcomes for lung cancer [Table 9]

[0106] A similar analysis was performed on normal lung versus adenocarcinoma samples as shown in Tables 10 and 11. Samples were identified with an accuracy of 92.2%, a sensitivity of 88.2%, a specificity of 93.6%, and an AUC of 0.98. Table 10: Mass-to-charge values ​​(m / z) and coefficients of lung cancer for normal lung vs. adenocarcinoma [Table 10] Table 11: Tissue sample predictions to actual outcomes for lung squamous cell carcinoma [Table 11]

[0107] A similar analysis was performed on normal lung versus squamous samples as shown in Tables 12 and 13. Samples were identified with an accuracy of 93.8%, a sensitivity of 88.2%, a specificity of 95.7%, and an AUC of 0.93. Table 12: Mass-to-charge values ​​(m / z) and coefficients of lung cancer for normal lung vs. lung squamous cell carcinoma [Table 12] Table 13: Tissue sample predictions versus actual outcomes for lung cancer [Table 13]

[0108] Similar analyses were performed with ovarian, thyroid, and breast cancers as with the lung cancer analysis above, and the respective m / z peaks and coefficients for each set of samples are shown. Ovarian cancer samples were detected with 94.7% accuracy, 100% sensitivity, 89.7% specificity, and an AUC of 0.98. Thyroid cancer samples were detected with 94.7% accuracy, 90.9% sensitivity, 96.3% specificity, and an AUC of 0.93. Finally, breast cancer samples were detected with 95.6% accuracy, 87.5% sensitivity, 100% specificity, and an AUC of 1.00. Table 14: Mass-to-charge values ​​(m / z) and coefficients for ovarian cancer [Table 14] Table 15: Tissue sample predictions to actual outcomes for ovarian cancer [Table 15] Table 16: Mass-to-charge values ​​(m / z) and coefficients of thyroid cancer relative to normal thyroid versus benign tumors [Table 16] Table 17: Tissue sample predictions versus actual calls for normal thyroid versus benign tumors [Table 17] Table 18: Mass-to-charge values ​​(m / z) and coefficients of thyroid cancer for normal thyroid versus malignant tumors [Table 18] Table 19: Tissue sample predictions versus actual call for normal thyroid versus benign tumors [Table 19] Table 20: Mass-to-charge values ​​(m / z) and coefficients of thyroid cancer relative to normal breast vs. breast cancer [Table 20] Table 21: Tissue sample predictions for normal breast vs. actual call for breast cancer [Table 21]

[0109] Example 5: Spatial resolution of the MasSpec Pen system The spatial resolution of the MasSpec Pen system was tested to determine that even higher spatial resolution could be determined using specific locations. Testing was performed using white matter versus gray matter in mouse brains. Shown in Figures 11A-11E are the brain sections that were tested using locations of specific sizes. In particular, sample location 1 shows that the location was composed primarily of gray matter.

[0110] Example 6: Non-destructive molecular analysis of tissue samples The MasSpec Pen was designed to operate directly on tissue samples, regardless of tissue hardness and morphology. The performance of the MasSpec Pen was tested to analyze soft tissue samples (0.1-5 g) from various organs, including mouse brain and human breast, thyroid, lung and ovarian tissues. Tissue analysis was performed in ambient conditions with a simple one-step experiment following the same automated operating steps described previously. The MasSpec Pen tip was gently brought into contact with the surface of the tissue sample for a period of 3 s during which extraction took place. Mass spectra obtained for regions of gray matter in mouse brain were reproducible (RSD=4.6%, n=10) and highly similar (cosine similarity of 0.93) to mass spectra of mouse brain tissue sections (Figure 4), thereby indicating that the extraction process at the tissue surface is efficient, regardless of tissue shape and hardness. Similarly, MasSpec Pen analysis of human tissue samples, particularly tissues composed of epithelial and cancer cells, provided rich molecular information. Non-cancerous tissue samples composed mainly of soft connective tissues such as stroma, provided less abundant mass spectral profiles. In particular, many of the normal and cancerous breast tissue samples analyzed exhibited fat content, which is not miscible with water and therefore resulted in less abundant total ion counts in the mass spectra when compared to breast cancer tissue or normal breast gland.

[0111] Visual and microscopic inspection of all tissue samples after MasSpec Pen analysis showed no detectable damage to the morphology of the tissue samples in the examined areas. Figure 15 shows optical images obtained from lung tissue samples before, during, and after MasSpec Pen analysis. Although no visible damage was observed to the tissue in the analyzed areas, a rich mass spectral profile was obtained (Figure 15). It should be noted that the automated and time-controlled operating steps of the MasSpec Pen prevent tissue damage, since the tissue is only exposed to small water droplets and no vacuum is used to transport the droplets from the reservoir to the mass spectrometer. Thus, these results provide evidence that the MasSpec Pen is a non-destructive approach to obtain rich molecular information from tissue samples.

[0112] Example 7: Molecular diagnosis and statistical prediction of cancer in human tissues We next evaluated whether molecular information obtained from human tissue samples using the MasSpec Pen could aid in diagnosis and predict disease status. A total of 253 human tissue samples were analyzed using the MasSpec Pen (Figure 11), including 95 lung samples (47 normal and 48 cancer samples, including 17 adenocarcinoma, 17 squamous cell carcinoma, and 14 cancer samples of other histological subtypes), 57 ovarian samples (29 normal and 28 HGSC), 57 thyroid samples (27 normal, 11 follicular thyroid adenoma, and 18 papillary thyroid carcinoma), and 45 breast samples (29 normal and 16 ductal carcinoma). Patient demographic information is shown in Table 6. After MasSpec Pen analysis, the analyzed area was demarcated and illustrated by a series of optical images. Parallel pieces of the samples were then frozen, sectioned at the demarcated area, H&E stained, and evaluated by histopathology to derive a diagnosis. Only samples with major cellular composition and unequivocal diagnosis were used to construct a molecular database. Histologically verified mass spectra obtained for cancer samples showed molecular species identified as several lipids and metabolites previously shown as potential disease markers using ambient ionization MS techniques. For lung cancer tissue, characteristic molecular markers such as m / z 863.565 identified as PI (36:1), m / z 773.542 identified as PG (36:2), m / z 747.514 identified as PG (34:1) and fatty acids such as m / z 281.249 identified as FA (18:1) were observed (Figure 15 and Table 4). For normal lung, m / z 885.550 identified as PI (38:4) and m / z 744.552 identified as PE (36:1) were observed. Mass spectra obtained for breast cancer tissues showed diagnostic lipid markers including m / z 885.550 identified as PI(38:4), m / z 863.565 identified as PI(36:1), m / z 773.542 identified as PG(36:2), and several FAs such as m / z 303.233 identified as FA(20:4), and m / z 281.249 identified as FA(18:1), previously shown by DESI-MSI (29, 30) (Table 5).PCA performed on the data obtained for all 253 human tissue samples analyzed showed a separation between cancer and normal tissue for each organ (Figure 11).

[0113] To evaluate whether the MasSpec Pen molecular signature can be used to predict cancer and normal tissues, the Lasso method was applied to build a classification model using a histologically verified mass spectral database. The performance of the model was evaluated by a leave-one-patient-out cross-validation approach and was judged by the sensitivity and specificity for cancer, as well as the accuracy and AUC (Table 22). For breast cancer (n=45), a sensitivity of 87.5%, specificity of 100% (AUC=1.0), and overall accuracy of 95.6% were achieved, which is similar to results reported using DESI-MSI (98.2% accuracy, n=126) (Guenther et al., Cancer Research, 75, 2015), iKnife (95.5% accuracy, n=10) (Balog et al., Science Translational Medicine, 5, 2013), and MALDI imaging of lipids and proteins (94.1% accuracy, n=68) (31). For HGSC (n=57), a sensitivity of 100%, a specificity of 89.7%, and an accuracy of 94.7% were achieved (AUC=0.98), which is also similar to the classification results obtained by DESI-MSI (97.1% accuracy, n=31) (Sans et al., Cancer Research, 2017). For lung cancer (n=956), a sensitivity of 98.097.9%, a specificity of 95.7%, and an accuracy of 96.89% were achieved (AUC=0.97). When predicting based on lung cancer histological subtypes, an accuracy of 93.8% and 92.2% was achieved for squamous cell carcinoma and adenocarcinoma, respectively. The thyroid tumor samples investigated included benign follicular thyroid adenoma (FTA) and malignant papillary thyroid carcinoma (PTC) samples. A classifier was built for each, obtaining an accuracy of 94.7% for FTA and 97.8% for PTC. Overall, a sensitivity of 96.4%, a specificity of 96.2% and an accuracy of 96.3% were achieved for all four types of cancer investigated. These results demonstrate that the molecular information obtained from human tissue samples by the MasSpec Pen is highly useful for cancer prediction.Furthermore, the results show that the statistical classifiers built on molecular data obtained using the MasSpec Pen are robust and can be used in automated approaches for rapid clinical diagnosis of tissue samples.

[0114] Table 22: Description of samples and results obtained using the MasSpec Pen. Showing pathology diagnosis, number of patient samples, as well as sensitivity, specificity, accuracy, and area under the curve of Lasso predictions obtained using a leave-one-out cross-validation approach. [Table 22]

[0115] Example 8: Intra-sample analysis of histologically distinct pericancerous tissue regions The ability of the MasSpec Pen to identify histologically distinct regions was evaluated in one human tissue sample containing a region of HGSC adjacent to normal ovarian stromal tissue. Five consecutive locations of the tissue sample as demarcated in the optical image shown in FIG. 14A were analyzed using a MasSpec Pen with a diameter of 1.5 mm. Tissue sections of the sample containing the area analyzed by the MasSpec Pen were subjected to H&E staining and evaluated by histopathology. Locations 1 and 2 were diagnosed as normal stroma by an expert pathologist, while locations 4 and 5 were diagnosed as HGSC. Location 3 was at the border between the cancerous and normal stromal tissue regions, showing approximately 50% tumor tissue and approximately 50% normal stromal tissue. FIG. 14B shows the mass spectra obtained for locations 1, 3, and 5. The spectrum obtained for location 5, HGSC, shows the characteristic lipid markers detected in the HGSC tissue analyzed ex vivo to build a statistical classifier (Table 3). The mass spectrum obtained for site 1, diagnosed as normal ovarian stromal tissue, showed less abundant molecular ions also observed for the stromal tissue analyzed ex vivo. Site 3 showed a molecular profile characteristic of HGSC with low total abundance due to the contribution of normal stromal tissue present in the analyzed area. The mass spectra obtained for the five sites were then evaluated by our ovarian cancer molecular classifier as an independent validation set. Notably, it properly classified the predicted sites 1 and 2 as normal and 3, 4, and 5 as cancer (Figure 14C). Similar results were obtained for different tissue samples including histologically distinct regions (Figure 19). These results indicate that the molecular information obtained by the MasSpec Pen can be used to detect cancer in the border zone with a mixed composition of normal and cancer cells.

[0116] Example 9: In vivo analysis of a mouse model of human breast cancer during surgery The MasSpec Pen was designed with biocompatible materials to ensure full suitability as an in vivo molecular diagnostic tool. The MasSpec Pen was tested for in vivo tissue analysis using a mouse model of human breast cancer. BT474 HER2+ breast cancer cells were implanted subcutaneously in athymic nude mice (n=3). 250mm 3 Tumors were allowed to grow for 4 weeks until an average of 1000 μg / kg / day was reached. All surgery and MasSpec Pen analysis procedures were performed under anesthesia. After dissecting the skin flap around the tumor using a surgical blade, the skin flap was carefully dissected away from the surface of the tumor. The exposed tumor was then analyzed using the MasSpec Pen following the same automated experimental steps previously described. Figure 16A shows optical images of an anesthetized animal before the start of surgery, before analysis (and after surgical removal of the skin), during MaSpec Pen analysis, and after analysis. Several tissue regions were analyzed for each animal studied, including the top of the tumor, the center of the tumor after partial tumor removal, as well as multiple locations of adjacent normal soft connective tissue. Mass spectra obtained for tumor regions show many molecular species observed in human breast tissue with a profile that is clearly different from that obtained for adjacent normal soft connective tissue regions (Figure 16B). No observable macroscopic or microscopic damage due to MasSpec Pen analysis to the analyzed tissue areas was detected using optical microscopy, as shown by the obtained optical images of H&E stained tissue sections (Figure 20). Furthermore, no obvious effects on the animal's health due to MasSpec Pen analysis during surgery were observed. After the in vivo analysis, freshly excised tumor samples were also analyzed ex vivo, obtaining mass spectra containing lipid species in common with those observed in the in vivo analysis, despite variations in relative abundance, likely due to the reanalysis process of the same tissue areas (Figure 21). These results suggest that the MaSpec Pen is suitable for in vivo molecular evaluation and cancer diagnosis.

[0117] Example 10: Materials and Methods Study Design: The purpose of this study is to evaluate the potential of novel mass spectrometry-based probes for non-destructive analysis and diagnosis of cancer in human tissue samples. The study investigated the molecular profile of human tissue samples from 282 patients, including normal and cancerous breast, lung, thyroid, and ovarian tissues. All patient samples were obtained under approved Institutional Review Board (IRB) protocols from the Cooperative Human Tissue Network (CHTN), Asterand Biosciences (Detroit, MI), MD Anderson Tissue Bank, and Baylor College of Medicine Tissue Bank. Mass spectra obtained using the MasSpec Pen on tissue samples were normalized, background subtracted, and analyzed using statistical techniques to build classification models. Board-certified pathologists (JL, WY, and NC) evaluated H&E stained tissue sections from the analyzed tissue samples. All information about the acquisitions from the mass spectrometry analysis was blinded to the pathologists. Samples were excluded from statistical analysis if they were judged by the pathologist to have substantial heterogeneity in cellular composition, which included 28 samples. In vivo animal model experiments were performed under approved Institutional Animal Care and Use Committee (IACUC) protocols.

[0118] Design and Engineering of the MasSpec Pen: A 3D printer (Model uPrint SE plus) was used to print the key component--the PDMS (Dow Corning, Midland, MI, USA) probe tip. The pen tip was fabricated by casting an elastomer through a negative model, followed by dissolving the model. The negative model was designed using SolidWorks computer-aided design (CAD) software, and then fused with the 3D printed deposit using ABS plastic (Stratasys, Eden Prairie, MN, USA) and soluble support material. To remove the support material, the parts were then washed at 70°C for 24 hours using a support removal device (SCA-1200HT, SCA) and solvent (EcoWorks) until the support material was completely dissolved. For casting, a mixture of PDMS elastomer base and curing agent (Sylgard 184, Dow Corning) was prepared in a weight ratio of 10:1, respectively. The mixture was poured onto the 3D printed model and cured in an oven (10GCE-LT, Quincy Lab) at 74 °C for 1 h, then placed in a closed container with acetone (Fisher Scientific, Waltham, MA, USA) to dissolve. A final cleaning step was to sonicate the tip in acetone to remove any remaining ABS. A PTFE tube (ID 1 / 32 inch, OD 1 / 16 inch, Cole-Parmer, Vernon Hills, IL, USA) was inserted directly into the probe tip for the experiment.

[0119] Data Acquisition: All experiments were performed on a Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Full scans were performed in the range of m / z 120-1800 using a resolution of 140,000, a capillary temperature of 350°C, and an S-lens RF level of 100. Wild-type mouse brain was purchased from BioreclamationIVT (Westbury, NY). A total of 282 human tissue samples including frozen breast, thyroid, ovary, and lung were obtained and stored in a -80°C freezer until analysis, where the samples were thawed at room temperature. The tissue was placed on a surface and analyzed by MasSpec Pen using the experimental steps indicated. After the experiment, the tissue area analyzed was annotated, frozen, and 16 μm tissue sections were made using a CryoStar™ NX50 cryostat. Further tissue sections of different areas of the tissue pieces were obtained for MS analysis. The tissue sections were kept frozen until analysis, where the sections were placed at room temperature and analyzed by MasSpec Pen. The tissue sections were then stained with H&E and evaluated by histopathology. The pathological diagnosis was used as the reference for the molecular database.

[0120] In vivo experiments: In vivo experiments were performed during surgical removal of tumors using a mouse animal model while the mice were under anesthesia (2% isoflurane, 98% O2). BT474 HER2+ cells were grown to 80-90% confluency in modified minimum essential medium (IMEM, Invitrogen, Carlsbad, CA) supplemented with 10% FBS, 1% L-glutamine, and 1% insulin at 5% O2 and 37°C. Cells were counted using a hemocytometer and trypan blue dye exclusion. Female athymic nude mice (N=3) were implanted subcutaneously at the nape of the neck with 0.72 mg of 60-day release 17β-estradiol pellets (Innovative Research of America, Sarasota, FL). Approximately 24 hours later, BT474 breast cancer cells (10 7) was injected subcutaneously into the right flank of the mice (100 μL total injection). Tumors were grown to a diameter of 0.7–1.0 cm (250 mm 3 The mice were observed for growth once a week until they reached a mean of 100% (average of 100% keratinocyte size). At that point, all surgical procedures were performed while the mice were under anesthesia (2% isoflurane, 98% O2). A surgical blade was used to incise a flap of skin leaving an estimated 1-2 cm gap around the tumor, which was then dissected away from the surface of the tumor. The skin was folded back to expose the tumor and adjacent normal tissue, which was analyzed in several areas using a MasSpec Pen. Small pieces of the tumor were then excised using a scalpel and analyzed ex vivo. For diagnosis, the tumor tissue areas analyzed by the MasSpec Pen were annotated, snap frozen, sectioned, and subjected to H&E staining.

[0121] Statistical analysis: The molecular database was constructed using the average of three mass spectra obtained during each 10-second MasSpec Pen analysis. Xcalibur raw data were converted to Microsoft Excel spreadsheet format. The entire mass range of the spectra was divided into bins by rounding the m / z values ​​to two decimal places. All mass spectra were first normalized according to the total ion count (TIC) or to the absolute intensity of m / z 885.55 to account for small variations in signal intensity that may occur between experiments. Background peaks as well as peaks that did not appear in at least 10% of the analyzed samples were then excluded to reduce random noise.

[0122] For each tissue section (breast or thyroid), four representative mass spectra of each tissue section analyzed were imported into metaboanalyst (http: / / www.metaboanalyst.ca / ) for principal component analysis (PCA) using the website's built-in functions. Score and loading plots were generated by the website for each tissue type. For each soft tissue sample type (breast, thyroid, lung, and ovary), the data was imported into the R programming language. PCA was performed by centering the preprocessed data to mean 0 and calculating the principal components using the prcomp function in R. The three principal components were first visualized using the rgl and pca3d packages for R. For tissue classification, the Lasso method was applied using the glmnet package from the CRAN R language library. Models generated using Lasso are easier to interpret than other regularization methods because they result in "sparse" models, i.e., models that include only a subset of the features. A mathematical weight for each statistically informative feature is calculated by Lasso according to the importance that the mass spectral feature has in characterizing a particular class (cancer vs. normal, or cancer subtype vs. normal). Classification was performed using a leave-one-out cross-validation approach to evaluate the predictive accuracy within the training set. The performance of the trained classifiers was judged by sensitivity, specificity, accuracy, and AUC. ...

[0123] All of the methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. Although the compositions and methods of the present invention have been described in the preferred embodiments section, it will be apparent to those skilled in the art that variations may be applied to the methods and steps or sequence of steps of the methods described herein without departing from the concept, spirit and scope of the present invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while still achieving the same or similar results. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the present invention as defined by the appended claims.

Claims

1. 1. An apparatus for preparing a sample for mass spectrometry analysis, comprising: a chamber containing a solvent; A pressurized gas supply; A mass spectrometer; a probe having a reservoir, a first conduit, a second conduit and a third conduit; Including, the reservoir is in fluid communication with the first conduit, the second conduit, and the third conduit; the first conduit is in fluid communication with the chamber; the second conduit in fluid communication with a pressurized gas supply; The apparatus, wherein the third conduit is in fluid communication with the mass spectrometer.

2. The apparatus of claim 1 , wherein the apparatus is not coupled to an ionization source.

3. The apparatus of claim 1 further coupled to an ionization source.

4. The device of claim 1 , wherein the probe is contained in a housing designed to be handheld.

5. The apparatus of claim 1 , wherein the probe is contained within a housing designed to couple with a laparoscopic surgical device.

6. The apparatus of claim 1 , wherein the reservoir is configured to form and hold droplets of the solvent.

7. The apparatus of claim 1 , wherein the pressurized gas supply provides gas to the probe at a pressure between 0.1 psig and 5.0 psig.

8. The apparatus of claim 1 , wherein the pressurized gas supply provides gas to the probe at a pressure between 0.5 psig and 2.5 psig.

9. The apparatus of claim 1 , wherein the pressurized gas supply provides gas to the probe at a pressure less than 100 psig.

10. The apparatus of claim 1 , wherein the pressurized gas supply provides air, nitrogen or carbon dioxide to the probe.

11. The apparatus of claim 1 , further comprising a pump configured to move a separate volume of the solvent from the chamber to the first conduit.

12. 12. The apparatus of claim 11, wherein the separate volume of the solvent provided by the pump passes from the first conduit to the probe reservoir, where the separate volume of the solvent is in direct contact with a surface.

13. The device of claim 12 , wherein the surface is a tissue site.

14. The apparatus of claim 1 , further comprising a first valve configured to control flow from the third conduit to the mass spectrometer.

15. 15. The apparatus of claim 14, wherein the third conduit is under vacuum when the first valve is in an open position.

16. The apparatus of claim 1 , further comprising a second valve configured to control a flow of pressurized gas through the second conduit.

17. The apparatus of claim 1 , wherein the solvent comprises water.

18. The apparatus of claim 1 , wherein the solvent comprises ethanol.

19. The device of claim 1 , wherein the solvent comprises an aqueous mixture comprising 1 to 25% ethanol.

20. The device of claim 1 , wherein the probe is formed from a composition including polydimethylsiloxane (PDMS) and / or polytetrafluoroethylene (PTFE).

21. The device of claim 1 , wherein the probe is disposable.

22. The device of claim 1 , wherein the probe comprises a removable retrieval tip.

23. The device of claim 1 , wherein the reservoir has a volume between 5.0 microliters and 20 microliters.

24. The apparatus of claim 1 , wherein the probe comprises a tracking device configured to track a position of the probe.

25. a solvent flow from the chamber to the reservoir through the first conduit; a flow of pressurized gas from the pressurized gas supply through the second conduit to the reservoir; and a sample flow from the reservoir through the third conduit to the mass spectrometer; The apparatus of claim 11 , further comprising a control system configured to control

26. The control system includes: Controlling the solvent flow at a flow rate between 200 and 400 microliters per minute for a time period between 1 and 3 seconds; controlling said pressurized gas flow at a flow rate between 0.1 and 15 psig for a time between 10 and 15 seconds; 26. The apparatus of claim 25, configured to control the sample flow for a time period between 10 and 15 seconds.

27. 26. The apparatus of claim 25, wherein the control system comprises a pedal to initiate solvent flow.

28. The apparatus of claim 1 , wherein the mass spectrometer is in electronic communication with a computer capable of providing sample analysis.

29. 30. The apparatus of claim 28, wherein the computer provides a visual or audio indication of the sample analysis.

30. The apparatus of claim 1 , further comprising a waste container in fluid communication with the third conduit.

31. 31. The apparatus of claim 30, further comprising a valve configured to divert fluid from the third conduit to the waste container.

32. 31. The apparatus of claim 30, further comprising a pump configured to remove contents of the waste container.

33. The apparatus of claim 1 , further comprising a pump in fluid communication with the third conduit.

34. 34. The apparatus of claim 33, wherein the pump is configured to increase the velocity of contents within the third conduit.

35. The apparatus of claim 1 , further comprising a heating element coupled to the third conduit.

36. 36. The apparatus of claim 35, wherein the heating element is a heating wire.

37. The apparatus of claim 1 , further comprising an ionization device in fluid communication with the third conduit.

38. 38. The apparatus of claim 37, wherein the ionization device is an electrospray ionization (ESI) device.

39. 38. The apparatus of claim 37, wherein the ionization device is an atmospheric pressure chemical ionization (APCI) device.

40. 38. The apparatus of claim 37, wherein the ionization device is for forming a spray proximate an inlet to a mass spectrometer.

41. The apparatus of claim 1 , wherein the third conduit is not directly coupled to the mass spectrometer.

42. The apparatus of claim 1 , further comprising a Venturi device in fluid communication with the third conduit.

43. The apparatus of claim 1 , wherein the apparatus does not include a device for application of ultrasonic or vibration energy.

44. 1. A method for evaluating a tissue sample from a subject, comprising: (a) applying a fixed or discrete volume of a solvent to a tissue site of said subject; (b) recovering the applied solvent to obtain a liquid sample; (c) subjecting the sample to mass spectrometry analysis; The method comprising:

45. 45. The method of claim 44, wherein the fixed or discrete volume of solvent is not applied as a spray.

46. 45. The method of claim 44, wherein the fixed or discrete volume of solvent is applied as a droplet.

47. 45. The method of claim 44, wherein the fixed or discrete volume of solvent is applied using a pressure of less than 100 psig.

48. 45. The method of claim 44, wherein the fixed or discrete volume of solvent is applied using a pressure of less than 10 psig.

49. 45. The method of claim 44, wherein the fixed or discrete volumes of solvent are applied using a mechanical pump to move the solvent through a solvent conduit.

50. 45. The method of claim 44, wherein recovering the applied solvent comprises applying negative pressure to draw the sample into a collection conduit and / or applying gas pressure to push the sample into a collection conduit.

51. 45. The method of claim 44, wherein recovering the applied solvent comprises applying negative pressure to draw the sample into a collection conduit and applying positive pressure to push the sample into a collection conduit.

52. 51. The method of claim 50, wherein the solvent is applied through a solvent conduit that is different from the collection conduit.

53. 53. The method of claim 52, wherein the gas pressure is applied through a gas conduit that is different from the solvent conduit and the recovery conduit.

54. 51. The method of claim 50, wherein applying gas pressure to force the sample into a collection conduit comprises applying a pressure of less than 100 psig.

55. 45. The method of claim 44, wherein the method causes no detectable physical damage to the tissue.

56. 45. The method of claim 44, wherein the method does not include application of ultrasonic or vibrational energy to the tissue.

57. 45. The method of claim 44, wherein the solvent is sterile.

58. 45. The method of claim 44, wherein the solvent is a pharma- ceutically acceptable formulation.

59. 59. The method of claim 58, wherein the solvent is an aqueous solution.

60. 60. The method of claim 59, wherein the solvent is sterile water.

61. 60. The method of claim 59, wherein the solvent consists essentially of water.

62. 60. The method of claim 59, wherein the solvent comprises about 1 to 20% alcohol.

63. 63. The method of claim 62, wherein the alcohol comprises ethanol.

64. 45. The method of claim 44, wherein the individual volumes of solvent are between about 0.1 and 100 μL.

65. 65. The method of claim 64, wherein the individual volumes of solvent are between about 1 and 50 μL.

66. 45. The method of claim 44, wherein recovering the applied solvent is between 0.1 and 30 seconds after the applying step.

67. 67. The method of claim 66, wherein recovering the applied solvent is between 1 and 10 seconds after the applying step.

68. 45. The method of claim 44, wherein the tissue site is an internal tissue site being surgically evaluated.

69. 45. The method of claim 44, further comprising collecting multiple fluid samples from multiple tissue sites.

70. 70. The method of claim 69, wherein the liquid sample is collected by a probe.

71. 71. The method of claim 70, wherein the probe is washed between collection of different samples.

72. 71. The method of claim 70, wherein the probe is disposable and is replaced between collection of different samples.

73. 71. The method of claim 70, wherein the probe comprises a collection tip, further comprising removing the collection tip from the probe after the liquid sample has been collected.

74. 70. The method of claim 69, wherein the plurality of tissue sites comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 tissue sites.

75. 75. The method of claim 74, wherein the plurality of tissue sites surround a surgically excised tissue cut.

76. 76. The method of claim 75, wherein the resected tissue is a tumor.

77. 45. The method of claim 44, further defined as an intraoperative method.

78. 45. The method of claim 44, wherein the mass spectrometry comprises ambient ionization MS.

79. 45. The method of claim 44, wherein subjecting the sample to mass spectrometry analysis comprises determining a profile corresponding to the tissue site.

80. 80. The method of claim 79, further comprising comparing the profile to a reference profile to identify a tissue site containing diseased tissue.

81. 81. The method of claim 80, further comprising excising a tissue site identified as containing diseased tissue.

82. The method according to claim 44, wherein the method is carried out using an apparatus according to any one of claims 44 to 77.

83. 1. An ex vivo method for evaluating a tissue sample, comprising: (a) obtaining a plurality of fluid samples from a plurality of tissue sites of a subject; (b) subjecting the plurality of fluid samples to mass spectrometry to obtain a plurality of profiles corresponding to the tissue sites; (c) comparing the plurality of profiles to a reference profile to identify tissue sites containing diseased tissue; The method comprising:

84. 70. The method of claim 69, wherein the liquid sample is contained in a solvent.

85. 70. The method of claim 69, wherein the diseased tissue comprises cancer cells.

86. 70. The method of claim 69, wherein the diseased tissue comprises lung, ovarian, or thyroid cancer cells.

87. 1. A method for obtaining a mass spectrometry profile, comprising: (a) applying a discrete volume of solvent to an assay site using a probe; (b) obtaining a liquid sample using the probe to collect the applied solvent; (c) subjecting the liquid sample to mass spectrometry analysis; The method comprising:

88. 88. The method of claim 87, wherein the solvent is an aqueous solution.

89. 89. The method of claim 88, wherein the solvent is sterile water.

90. 90. The method of claim 88, wherein the solvent consists essentially of water.

91. 90. The method of claim 88, wherein the solvent comprises about 1 to 20% alcohol.

92. 92. The method of claim 91, wherein the alcohol comprises ethanol.

93. 88. The method of claim 87, wherein the fixed or separate volume of solvent is between about 0.1 and 100 μL.

94. 94. The method of claim 93, wherein the fixed or separate volume of solvent is between about 1 and 50 μL.

95. 88. The method of claim 87, wherein recovering the applied solvent is between 0.1 and 30 seconds after the applying step.

96. 96. The method of claim 95, wherein recovering the applied solvent is between 1 and 10 seconds after the applying step.

97. 88. The method of claim 87, wherein the assay site is a tissue.

98. 90. The method of claim 87, further comprising collecting a plurality of fluid samples from a plurality of assay sites.

99. 99. The method of claim 98, wherein the probe is washed between collection of different samples.

100. 99. The method of claim 98, wherein the probe is disposable and is replaced between collection of different samples.

101. 90. The method of claim 87, wherein the probe comprises a collection tip, further comprising removing the collection tip from the probe after obtaining the liquid sample.

102. 99. The method of claim 98, wherein the plurality of tissue sites comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 assay sites.

103. 88. The method of claim 87, wherein the mass spectrometry comprises ambient ionization MS.

104. 88. The method of claim 87, wherein subjecting the sample to mass spectrometry analysis comprises determining a profile corresponding to the tissue site.

105. 105. The method of claim 104, further comprising comparing the profile to a reference profile.

106. The method according to claim 87, wherein the method is carried out using an apparatus according to any one of claims 1 to 26.

107. 1. A method for identifying a lung cancer sample, comprising: (a) obtaining at least one sample; (b) subjecting the at least one sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m / z) ratios; The method of claim 1, wherein the sample is identified as a lung cancer sample if the profile comprises one or more mass-to-charge (m / z) ratios selected from the group consisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 861.55, 863.57, 885.55, and 886.

55.

108. The method of claim 107, wherein the mass spectrometry profile is obtained according to the method of any one of claims 87 to 105.

109. 108. The method of claim 107, wherein the at least one sample is a liquid sample.

110. 110. The method of claim 109, wherein the multiple liquid samples are subjected to mass spectrometry analysis.

111. 108. The method of claim 107, wherein the sample is identified as a lung cancer sample if the profile comprises at least five mass-to-charge (m / z) ratios selected from the group consisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 861.55, 863.57, 885.55, and 886.

55.

112. 108. The method of claim 107, wherein the sample is identified as a lung cancer sample if the profile comprises at least ten mass-to-charge (m / z) ratios selected from the group consisting of 175.02, 187.01, 201.04, 215.03, 306.08, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 861.55, 863.57, 885.55, and 886.

55.

113. 108. The method of claim 107, wherein the sample is identified as a lung cancer sample if the profile comprises mass-to-charge (m / z) ratios of 175.02, 187.01, 201.04, 215.03, 313.16, 330.98, 332.90, 357.10, 409.23, 615.17, 722.51, 744.55, 747.52, 748.52, 771.52, 773.53, 863.57, 885.55, and 886.

55.

114. 108. The method of claim 107, wherein the sample is identified as a lung adenocarcinoma sample if the profile includes mass-to-charge (m / z) ratios of 175.02, 201.04, 747.52, 773.53, and 885.

55.

115. 108. The method of claim 107, wherein the sample is identified as a lung squamous cell carcinoma sample if the profile includes mass-to-charge (m / z) ratios of 201.04, 306.08, 747.52, 773.53, 861.55, and 885.

55.

116. 108. The method of claim 107, wherein the sample is obtained from a subject.

117. 117. The method of claim 116, further comprising administering to the subject an anti-cancer therapy.

118. 1. A method for identifying an ovarian cancer sample, comprising: (a) obtaining at least one sample; (b) subjecting the at least one sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m / z) ratios; The method, wherein the sample is identified as an ovarian cancer sample if the profile comprises one or more mass-to-charge (m / z) ratios selected from the group consisting of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.

27.

119. The method of claim 118, wherein the mass spectrometry profile is obtained according to any one of claims 87 to 105.

120. 119. The method of claim 118, wherein the at least one sample is a liquid sample.

121. 121. The method of claim 120, wherein the multiple liquid samples are subjected to mass spectrometry analysis.

122. 119. The method of claim 118, wherein the sample is identified as an ovarian cancer sample if the profile comprises at least three mass-to-charge (m / z) ratios selected from the group consisting of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.

27.

123. 119. The method of claim 118, wherein the sample is identified as an ovarian cancer sample if the profile includes mass-to-charge (m / z) ratios of 124.01, 175.02, 175.03, 283.27, 313.16, and 341.

27.

124. 1. A method for identifying a thyroid cancer sample, comprising: (a) obtaining at least one sample; (b) subjecting the at least one sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m / z) ratios; The method of claim 1, wherein the sample is identified as a thyroid cancer sample if the profile comprises one or more mass-to-charge (m / z) ratios selected from the group consisting of 175.02, 191.02, 191.05, 283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.

48.

125. The method of claim 124, wherein the mass spectrometry profile is obtained according to any one of claims 87 to 105.

126. 125. The method of claim 124, wherein the at least one sample is a liquid sample.

127. 127. The method of claim 126, wherein the multiple liquid samples are subjected to mass spectrometry analysis.

128. 125. The method of claim 124, wherein the sample is identified as a thyroid cancer sample if the profile comprises at least five mass-to-charge (m / z) ratios selected from the group consisting of 175.02, 191.02, 191.05, 283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.

48.

129. 125. The method of claim 124, wherein the sample is identified as a benign thyroid cancer sample if the profile includes mass-to-charge (m / z) ratios of 175.02, 191.02, 191.05, 283.27, 341.27, 615.17, 822.47, and 822.

48.

130. 125. The method of claim 124, wherein the sample is identified as a malignant thyroid cancer sample if the profile includes mass-to-charge (m / z) ratios of 175.02, 283.27, 341.27, 353.16, 432.20, 433.21, 615.17, 822.47, and 822.

48.

131. 1. A method for identifying a breast cancer sample, comprising: (a) obtaining at least one sample; (b) subjecting the at least one sample to mass spectrometry analysis, thereby obtaining a mass spectrometry profile comprising a plurality of mass-to-charge (m / z) ratios; The method of claim 1, wherein the sample is identified as a breast cancer sample if the profile comprises one or more mass-to-charge (m / z) ratios selected from the group consisting of 187.04, 268.80, 279.92, 283.27, 341.27, 345.16, 381.21, 687.51, 742.54, and 766.

54.

132. The method of claim 131, wherein the mass spectrometry profile is obtained according to any one of claims 87 to 105.

133. 132. The method of claim 131, wherein the at least one sample is a liquid sample.

134. 134. The method of claim 133, wherein the multiple liquid samples are subjected to mass spectrometry analysis.

135. 132. The method of claim 131, wherein the sample is identified as a breast cancer sample if the profile comprises at least five mass-to-charge (m / z) ratios selected from the group consisting of 187.04, 268.80, 279.92, 283.27, 341.27, 345.16, 381.21, 687.51, 742.54, and 766.

54.

136. 132. The method of claim 131, wherein the sample is identified as a breast cancer sample if the profile includes mass-to-charge (m / z) ratios of 187.04, 268.80, 279.92, 283.27, 341.27, 345.16, 381.21, 687.51, 742.54, and 766.54.

Citation Information

Patent Citations

  • Method and system for forming a sample and aspirating it from the surface to be analyzed.

    JP2012519847A

  • Systems and methods for identifying biological tissues

    JP2012528320A

  • Method and system for surface sampling

    US20120080592A1